# A New Oral Treatment For Type II Diabetes Mellitus

> **NCT00111800** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 375 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Placebo
- **DRUG:** DEN 2.5 mg
- **DRUG:** DEN 7.5 mg
- **DRUG:** DEN 15 mg
- **DRUG:** DEN 30 mg
- **DRUG:** DEN 45 mg

## Key facts

- **NCT ID:** NCT00111800
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04-28
- **Primary completion:** 2006-07-01
- **Final completion:** 2006-07-21
- **Target enrollment:** 375 (ACTUAL)
- **Last updated:** 2018-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00111800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00111800, "A New Oral Treatment For Type II Diabetes Mellitus". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT00111800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*